Axitinib: all 159 studies that test it
Page 2 of 2. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.
- Seleno-L Methionine (SLM)-Axitinib-PembrolizumabActive, not recruitingNCT05363631Phase 1/2
- Optimizing Pembrolizumab Therapy With Timing and Intensification With AxitinibWithdrawnNCT05263609Phase 2
- A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell CarcinomaCompletedNCT05256472Phase 2
- Avelumab, Palbociclib and Axitinib in Advanced RCCWithdrawnNCT05176288Phase 2
- StrataPATH™ (Precision Indications for Approved Therapies)TerminatedNCT05097599Phase 2
- Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver MetastasisStatus unknownNCT05070221Phase 1
- Axitinib + Ipilimumab in Advanced MelanomaActive, not recruitingNCT04996823Phase 2
- Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell CarcinomaStatus unknownNCT04995016Phase 2
- TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)TerminatedNCT04873895Phase 1
- Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT04698213Phase 2
- A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced MelanomaCompletedNCT04640545Phase 1
- NPC - AXEL Study : Axitinib-AvelumabCompletedNCT04562441Phase 2
- A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell CarcinomaActive, not recruitingNCT04522323Phase 1
- Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell CancerCompletedNCT04394975Phase 3
- Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell CarcinomaStatus unknownNCT04385654Phase 2
- A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard TherapyCompletedNCT04258956Phase 2
- Pembrolizumab With Axitinib in Recurrent Endometrial CancerWithdrawnNCT04197219Phase 2
- Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaCompletedNCT04118855Phase 2
- Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant TumorsStatus unknownNCT04010071Phase 2
- Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/ParagangliomaActive, not recruitingNCT03839498Phase 2
- Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based ChemotherapyCompletedNCT03826589Not applicable
- Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the EndometriosisWithdrawnNCT03481842Phase 1/2
- Prior Axitinib as a Determinant of Outcome of Renal SurgeryActive, not recruitingNCT03438708Phase 2
- Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCCStatus unknownNCT03341845Phase 2
- Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent GlioblastomaCompletedNCT03291314Phase 2
- Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of GlioblastomaWithdrawnNCT03275558Phase 1
- Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell CarcinomaActive, not recruitingNCT03172754Phase 1/2
- Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic CarcinomaCompletedNCT02859012Phase 2
- Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14CompletedNCT02857712Phase 2
- The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCCCompletedNCT02814461Phase 1
- Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid LeukemiaTerminatedNCT02782403Phase 1
- Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic FactorsCompletedNCT02700568Phase 2
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)CompletedNCT02597322Phase 2
- Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell CarcinomaCompletedNCT02489695Phase 2
- Phase II Study on Axitinib in Advanced Solitary Fibrous TumorCompletedNCT02261207Phase 2
- VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid TumorsCompletedNCT02164838Phase 1
- A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With TemsirolimusCompletedNCT01798446Phase 2
- A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent GlioblastomaCompletedNCT01562197Phase 2
- Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose AxitinibCompletedNCT01540526Phase 1
- Study of Axitinib and Temsirolimus in Solid TumorsCompletedNCT01529138Phase 1
- Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal CancerCompletedNCT01486251Not applicable
- Axitinib as Maintenance Treatment in Patients With Metastatic CRCTerminatedNCT01483638Phase 2
- A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.WithdrawnNCT01441388Phase 1
- Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node MetastasisCompletedNCT01409200Phase 2
- Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +AxitinibCompletedNCT01352728Phase 2
- Study of Axitinib in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT01334112Phase 2
- Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid TumorsCompletedNCT01334073Phase 1
- Axitinib as Second-line Treatment for Advanced Hepatocellular CarcinomaCompletedNCT01273662Phase 2
- Nasopharyngeal Carcinoma (NPC) AxitinibCompletedNCT01249547Phase 2
- Standard Chemotherapy With of Without Axitinib in Malignant MesotheliomaCompletedNCT01211275Phase 1/2
- A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue SarcomasCompletedNCT01140737Phase 2
- A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy VolunteersCompletedNCT01020136Phase 1
- CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid TumorsCompletedNCT00949624Phase 1
- Axitinib Pharmacokinetics in Chinese Healthy VolunteersCompletedNCT00919204Phase 1
- Food Effect Study Of AG-013736 In Healthy VolunteersCompletedNCT00918632Phase 1
- A Bioequivalence Study Of AG-013736 Tablets In Healthy VolunteersCompletedNCT00905814Phase 1
- Pharmacodynamic Study of Axitinib in Patients With Advanced Solid MalignanciesCompletedNCT00859118Phase 1
- A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.WithdrawnNCT00386555Phase 2